pocketful logo
Ambalal Sarabhai Enterprises Ltd logo

Ambalal Sarabhai Enterprises Ltd

NSE: AMBASARABH BSE: 500009

₹24.99

(3.35%)

Sun, 15 Mar 2026, 00:27 pm

mtf coin illustrationMTF 5x

Company History

1977

  • The company was incorporated on 27th June as a private limited company.
  • The company's objects are the manufacture of drugs and pharmaceuticals, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass, and plastic containers and packaging materials.

1978

  • The acquisition of the undertakings from Ofisade became effective from 16th May.
  • The Company issued further 11% Non-Convertible bonds of the face value of Rs.166 lakhs.

1979

  • The Company acquired the entire shareholding of SG for a total consideration of Rs.229.71 lakhs.

1981

  • The Company proposed to undertake various schemes of expansion, diversification, modernisation, research, and development.
  • The Company received industrial licenses for the manufacture of several drugs and mini-computers/microprocessors-based systems.
  • SG Chemicals & Pharmaceuticals, Ltd. was amalgamated with the Company.
  • Standard Pharmaceuticals, Ltd. was amalgamated with the Company.
  • The Company issued secured Convertible Debentures of Rs.10 crores on rights basis.

1982

  • The fully automated synthetic detergent plant was commissioned in the last quarter of the year.
  • The Company proposed to manufacture sophisticated computer systems in collaboration with Sperry of U.S.A.
  • The Company proposed to amalgamate with Swastik Household & Industrial Products P. Ltd., SM Chemicals & Electronics P. Ltd., and Whitco, Ltd.

1983

  • The Scheme of Amalgamation of Swastik Household Industrial Products Pvt. Ltd. and S.M. Chemicals & Electronics Pvt. Ltd. with the Company was sanctioned.
  • 633,33,330 shares were allotted in part conversion of debenture.
  • 46,123 shares were allotted without payment in cash to shareholders of Standard Pharmaceuticals Ltd. on its merger.

1984

  • The Company issued 15% Secured non-convertible debentures for Rs.10 crores.

1985

  • The Company issued 15% Secured non-convertible debentures for Rs.10 crores.
  • A Scheme of Reorganisation of Ambalal Sarabhai Enterprises was evolved to divide operations between ASE and its subsidiaries.

1986

  • The Scheme of Amalgamation for the merger of ASE and its subsidiaries was sanctioned by the High Courts of Gujarat and Mumbai.

1987

  • The Gujarat High Court gave its sanction for the Scheme of Amalgamation.
  • Sarabhai Electronics Ltd. issued 35,82,536 equity shares to the shareholders of the Company.
  • 1,67,400 equity shares were allotted without payment in cash to members of SHIP Pvt. Ltd. and SMCPL on their merger.

1988

  • The Company suffered a severe setback due to non-availability of working funds.
  • The Company entered into an understanding with Bristol-Myers Squibb Corporation for technical know-how in pharmaceuticals.
  • The Company disinvested in its wholly owned subsidiary SG Chemicals and Dyes Trading Ltd.
  • The Company sold its shares in Swastik Surfactants Ltd. for a consideration of Re.1 crore.

1989

  • The Government granted an industrial license for the project.
  • The Company proposed to issue fresh equity to shareholders/public for the project.
  • The Company entered into technical collaboration agreements with Avesta and Pannevis.

1990

  • 171,29,622 shares were allotted as fully paid-up to bondholders of series 'A' and 'B' on redemption of the said bonds.

1991

  • The Company received permission under the FERA, 1973 for acquiring 6,000 equity shares of Synbiotics Ltd.
  • The Company revalued most of its assets, resulting in a surplus credited to capital reserve.

1993

  • 2,70,39,214 shares were allotted on conversion of 15% non-convertible debentures and 13.5% convertible debentures.

1994

  • The Company introduced highly purified insulin injections manufactured under technical collaboration with Biobras of Brazil.

1995

  • The Company launched a full range of highly purified procine insulin.
  • The Company started manufacturing human insulin products.
  • The Company launched an oral formulation 'Contramal' in collaboration with Grunenthal of Germany.
  • The Electronics division introduced an auto-scanning/computing Densitometer.

1996

  • The Company introduced new 'Cardiovascular' anti-inflammatory and antiheptic ulcer drugs.
  • The Company obtained industrial licenses for the manufacture of fatty acids, Sorbitol, and increcal.
  • The Company introduced new products, including extensions of existing products.

2000

  • The Company formed a veterinary products joint venture with Cadila Healthcare of the Zydus group.

2007

  • Ambalal Sarabhai Enterprises Ltd appointed Mr. B S Bohra as Additional Director of the Company.

2008

  • The Company acquired 100% paid-up share capital of Suvik Hi-tek Pvt. Ltd., making it a wholly owned subsidiary.

2012

  • Ms. Chaula Shastri joined the Board of Directors as a Whole-Time Director of the Company.

2016

  • The Company changed its registered office address from Sarabhai Campus Gorwa Road, Vadodara to Shanti Sadan Mirzapur Road, Ahmedabad.

2023

  • The Company launched new products 'Rapid Daignostics Product Range' A.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800